NASDAQ •
Healthcare •
Biotechnology •
Quote as of 07/28/2026 16:00
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization2,353.49 mln
Float23.74 mln
Earnings Date08/14/2026
1-Year Forecast
50.00
Modest upside
Relative Strength
93
/ 100
Top performer
Debt / Equity
-0.01
Negative equity
Dividend Yield
0.00%
No dividend
DPS
0.00
No dividend
Payout Ratio
0%
No payout
Business Description
Founded in 2020 and headquartered in Cambridge, Massachusetts, with operations in Denmark, Hemab Therapeutics is an early-stage medical company focused on developing new treatments for rare bleeding disorders. Its lead medicine, HMB-001, is currently being tested in clinical trials for two conditions that prevent blood from clotting properly, while a second treatment, HMB-002, targets Von Willebrand disease, another disorder that impairs the body's ability to stop bleeding. The company is also working on several additional treatments in earlier stages of research.
